A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Public ClinicalTrials.gov record NCT05665595. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.
Study identification
- NCT ID
- NCT05665595
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,594 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 19, 2023 (Actual)
- Primary completion
- Mar 6, 2024 (Actual)
- Completion
- Sep 24, 2025 (Actual)
- Last update posted
- Sep 10, 2026
2023 – 2025
United States locations
- U.S. sites
- 30
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Moores Cancer Center ( Site 0116) | La Jolla | California | 92093-0698 | — |
| The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123) | Los Angeles | California | 90025 | — |
| UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131) | Los Angeles | California | 90095 | — |
| California Pacific Medical Center - Pacific Campus ( Site 0111) | San Francisco | California | 94115 | — |
| UCSF Medical Center at Mission Bay ( Site 0130) | San Francisco | California | 94158 | — |
| The Melanoma & Skin Cancer Institute ( Site 0120) | Englewood | Colorado | 80113 | — |
| Georgetown University Medical Center ( Site 0144) | Washington D.C. | District of Columbia | 20007 | — |
| University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0110) | Miami | Florida | 33136 | — |
| Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 0124) | Tampa | Florida | 33612 | — |
| Northwestern Memorial Hospital ( Site 0109) | Chicago | Illinois | 60611 | — |
| Advocate Medical Group-Oncology ( Site 0102) | Park Ridge | Illinois | 60068 | — |
| University of Iowa-Holden Comprehensive Cancer Center ( Site 0107) | Iowa City | Iowa | 52242 | — |
| Henry Ford Hospital ( Site 0133) | Detroit | Michigan | 48202 | — |
| Comprehensive Cancer Centers of Nevada ( Site 0142) | Las Vegas | Nevada | 89169 | — |
| R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0132) | Lake Success | New York | 11042 | — |
| Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0146) | Mineola | New York | 11501 | — |
| Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0113) | New York | New York | 10016 | — |
| Icahn School of Medicine at Mount Sinai ( Site 0118) | New York | New York | 10029 | — |
| Weill Cornell Medical College ( Site 0115) | New York | New York | 10065 | — |
| Levine Cancer Institute ( Site 0138) | Charlotte | North Carolina | 28204 | — |
| Sanford Fargo Medical Center ( Site 0127) | Fargo | North Dakota | 58102 | — |
| Children's Hospital of Pittsburgh ( Site 0141) | Pittsburgh | Pennsylvania | 15224 | — |
| UPMC Hillman Cancer Center ( Site 0135) | Pittsburgh | Pennsylvania | 15232 | — |
| Sanford Cancer Center ( Site 0125) | Sioux Falls | South Dakota | 57104 | — |
| The West Clinic, PLLC dba West Cancer Center ( Site 0119) | Germantown | Tennessee | 38138 | — |
| St. Jude Children's Research Hospital ( Site 0106) | Memphis | Tennessee | 38105 | — |
| Vanderbilt University Medical Center ( Site 0139) | Nashville | Tennessee | 37232 | — |
| University of Texas MD Anderson Cancer Center ( Site 0145) | Houston | Texas | 77030 | — |
| Inova Schar Cancer Institute ( Site 0103) | Fairfax | Virginia | 22031 | — |
| University of Wisconsin Hospital and Clinics ( Site 0108) | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 175 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05665595, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05665595 live on ClinicalTrials.gov.